genosco.com Open in urlscan Pro
203.245.24.48  Public Scan

Form analysis
0 forms found in the DOM

Text Content

본문 바로가기




타이틀


메뉴

 * ABOUT
    * Mission and Values
    * History
    * Leadership
      
    * Contact

 * OUR SCIENCE
    * G-SMART Platform
    * Kinase Background

 * PIPELINE
    * Overview
    * Lazertinib
    * Cevidoplenib
    * SKI-G-801
    * ROCK2 Program
    * FGFR2/3 Program

 * PARTNERSHIP
 * INVESTORS
    * News
    * Publications
      
    * IR Contact

 * * ENG
   * KOR

ABOUT

 * Mission and Values
 * History
 * Leadership
   
 * Contact

OUR SCIENCE

 * G-SMART Platform
 * Kinase Background

PIPELINE

 * Overview
 * Lazertinib
 * Cevidoplenib
 * SKI-G-801
 * ROCK2 Program
 * FGFR2/3 Program

PARTNERSHIP

 * Partnership

INVESTORS

 * News
 * Publications
   
 * IR Contact

From Small Innovations to Pronounced Medical Breakthroughs
From Small Innovations to Pronounced Medical Breakthroughs

Based in Boston, Genosco is a clinical stage biotech specializing in

the discovery and development of novel kinase inhibitors for

patients with unmet medical needs

Based in Boston, Genosco is a clinical stage

biotech specializing in the discovery and development

of novel kinase inhibitors for patients with unmet

medical needs

 * 01.
   Experienced
   Team
   
   Dedicated team of experts in
   kinase targeted therapies

 * 02.
   Proprietary
   Discovery
   Platform
   
   G-SMART™ platform enables us
   to identify rare sequences and
   rapidly generate highly
   selective compounds

 * 03.
   Strong and
   Diverse
   Pipeline
   
   Multiple independent and
   partnered pipelines

 * 04.
   Proven Track
   Record
   
   Backed by successful
   out-licensing partnership

01.
Experienced
Team

Dedicated team of experts in
kinase targeted therapies

02.
Proprietary
Discovery
Platform

G-SMART™ platform enables us
to identify rare sequences and
rapidly generate highly
selective compounds

03.
Strong and
Diverse
Pipeline

Multiple independent and
partnered pipelines

04.
Proven Track
Record

Backed by successful
out-licensing partnership

G-SMART™ Platform
470+

Mapping / profiling of ATP
binding sites of 470+ human kinases

3,500+

Proprietary chemical
library of 3,500+ master scaffolds

Predictive modelling

to rapidly discover, test and
optimize selective compounds

View more
Lazertinib
Lazertinib
Cevidoplenib
SKI-G-801
ROCK2
FGFR2/3
Previous
EGFR
Lazertinib
Development Program
 * Non-Small Cell Lung Cancer (NSCLC)

View pipeline
SYK
SYK Inhibitor (Cevidoplenib)
Development Programs
 * Rheumatoid Arthritis (RA)
 * Immune Thrombocytopenia (ITP)

Other Indications
 * Systemic Lupus Erythematosus (SLE)
 * Sjogren’s Syndrome
 * Psoriasis
 * ANCA-associated Vasculitis (AAV)

View pipeline
FLT3
FLT3 Inhibitor (SKI-G-801)
Development Program
 * Acute Myeloid Leukemia (AML)

View pipeline
ROCK2
ROCK2 Inhibitor
Development Program
 * Idiopathic Pulmonary Fibrosis (IPF)

Other Indications
 * Cancer / Immuno-oncology
 * Nonalcoholic Steatohepatitis (NASH)
 * Central Nervous System (CNS)

View pipeline
FGFR2/3
FGFR2/3 Inhibitor
Development Program
 * Cholangiocarcinoma

Other Indications
 * Endometrial Cancer
 * Gastric Cancer
 * Breast Cancer
 * Bladder Cancer

View pipeline
Next
We are unified under the shared vision to improve patients’ quality of life
tomorrow, together.
To achieve this, it is important to focus on strengthening the discovery
platform based on cutting-edge science,
and to create an open and positive working environment where employees can
unleash their full creativity.
John Koh, CEO of Genosco
Press Release
 * Dec 01, 2022
   
   Yuhan’s Leclaza records 20.6-month mPFS as 1st-line NSCLC therapy
   
   View more
 * Jul 26, 2022
   
   Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT® and
   Lazertinib Combination
   
   View more

Genosco Inc. 43 Manning Rd, Billerica, MA 01821
 * Tel. (+1) 617-494-1460
 * Fax. (+1) 617-714-3443
 * E-mail. info@genosco.com

Copyright 2021 GENOSCO Inc. All rights reserved.

 *